Emergent BioSolutions (STU:ER4) Additional Paid-In Capital : €837 Mil(As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Additional Paid-In Capital?

Emergent BioSolutions's quarterly additional paid-in capital declined from Sep. 2023 (€843 Mil) to Dec. 2023 (€829 Mil) but then increased from Dec. 2023 (€829 Mil) to Mar. 2024 (€837 Mil).

Emergent BioSolutions's annual additional paid-in capital increased from Dec. 2021 (€734 Mil) to Dec. 2022 (€825 Mil) and increased from Dec. 2022 (€825 Mil) to Dec. 2023 (€829 Mil).

Emergent BioSolutions Additional Paid-In Capital Historical Data

The historical data trend for Emergent BioSolutions's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Additional Paid-In Capital Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

644.49

645.19

734.02

824.58

829.34

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															820.24	826.82	843.02	829.34	837.02

Emergent BioSolutions Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Emergent BioSolutions Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (STU:ER4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines